Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Journey Medical CorporationNASDAQ: DERM

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $10.11M fell 4.4% year over year, ahead of the -24.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.5% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.

Context

  • Selling, general & admin amounted to 71.7% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of $50.24M (+13.2%) for the fiscal year ending Dec 2026, a step up from the +10.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.11M+2.5% QoQ
Last fiscal yearDec 2025
$44.37M+10.4% YoY
LTMMar 2026
$31.85M-24.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%+5.9%+10.2 pp
1 year+10.4%+13.2%+2.9 pp
3-year CAGR-9.3%+33.0%+42.3 pp
5-year CAGR+21.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
44.37M USD
Year-over-year change
+10.4%
4-year CAGR
+2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.8% is the lowest of 10, against a peer median of +32.8%.
  • Selling, general & admin amounts to 49.2% of revenue for DERM, versus a peer median of 102.8%.
DERM Competitors
Selling, General & Admin for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGIOrganigram Global Inc.LTM Mar 2026CA$92.98M CAD+36.2%—33.9%
OSUROraSure Technologies, Inc.LTM Mar 2026$74.99M USD-2.4%-14.3%66.4%
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$52.43M USD+32.8%+31.8%102.8%
NYXHNyxoah S.A.LTM Mar 2026€51.66M EUR+54.2%+35.0%316.6%
DERMJourney Medical CorporationLTM Mar 2026$31.85M USD-24.8%-9.3%49.2%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$30.27M USD+4.4%+9.7%1705.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M USD+11.1%+24.6%82.5%
HSDTSolana CompanyLTM Mar 2026$25.32M USD+141.6%+29.5%264.1%
MDWDMediWound Ltd.LTM Mar 2026$14.41M USD+9.9%+10.3%99.5%
Peer median (excluding DERM) —+32.8%+27.1%102.8%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.13M73.67M79.18M56.13M61.86M
Cost of Revenue32.08M30.78M26.66M20.88M25.18M
Gross Profit31.05M42.89M52.52M35.26M36.68M
Gross Margin49.2%58.2%66.3%62.8%59.3%
Research & Development16.56M10.94M7.54M9.86M480K
Selling, General & Admin39.83M59.47M43.91M40.2M44.37M
Operating Expenses65.93M70.41M54.59M48.93M44.85M
Depreciation & Amortization2.56M4.37M3.86M3.52M4.35M
EBITDA(32.77M)(23.18M)1.92M(8.4M)(3.33M)
EBITDA Margin-51.9%-31.5%2.4%-15.0%-5.4%
Operating Income(34.88M)(27.52M)(2.07M)(13.68M)(8.17M)
Operating Margin-55.2%-37.4%-2.6%-24.4%-13.2%
Interest Income2K60K322K757K589K
Interest Expense7.03M2.02M1.7M2.7M3.7M
Other Income / Expenses(7.48M)(2.05M)(1.56M)(934K)(3.2M)
Income Before Tax(42.36M)(29.57M)(3.63M)(14.61M)(11.37M)
Pre-Tax Margin-67.1%-40.1%-4.6%-26.0%-18.4%
Income Tax Expense1.63M63K221K61K60K
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Net Margin-69.7%-40.2%-4.9%-26.1%-18.5%
EPS (Basic)(2.54)(1.69)(0.21)(0.72)(0.47)
EPS (Diluted)(2.54)(1.69)(0.21)(0.72)(0.47)
Weighted Avg Shares17.32M17.53M18.23M20.43M24.5M
Weighted Avg Shares (Diluted)17.32M17.53M18.23M20.43M24.5M

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.